Andres Maldonado
Stock Analyst at HC Wainwright & Co.
(2.08)
# 2,910
Out of 4,918 analysts
86
Total ratings
33.33%
Success rate
-2.15%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andres Maldonado
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IMAB I-Mab | Reiterates: Buy | $7 | $2.62 | +167.18% | 1 | Jul 9, 2025 | |
| IBRX ImmunityBio | Reiterates: Buy | $8 | $2.37 | +237.55% | 4 | Jun 4, 2025 | |
| AURA Aura Biosciences | Assumes: Buy | $22 | $6.75 | +225.93% | 1 | May 28, 2025 | |
| ZNTL Zentalis Pharmaceuticals | Reiterates: Buy | $10 | $1.34 | +646.27% | 1 | May 15, 2025 | |
| CRBP Corbus Pharmaceuticals Holdings | Maintains: Buy | $50 → $40 | $9.31 | +329.65% | 2 | May 7, 2025 | |
| TCRX TScan Therapeutics | Maintains: Buy | $15 → $10 | $1.62 | +517.28% | 1 | May 7, 2025 | |
| ERAS Erasca | Reiterates: Buy | $6 | $1.39 | +331.65% | 10 | Apr 30, 2025 | |
| FHTX Foghorn Therapeutics | Reiterates: Buy | $13 | $5.00 | +160.00% | 1 | Apr 30, 2025 | |
| STRO Sutro Biopharma | Reiterates: Neutral | $2 | $0.81 | +146.91% | 1 | Apr 29, 2025 | |
| TARA Protara Therapeutics | Reiterates: Buy | $23 | $3.06 | +651.63% | 1 | Apr 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $75 | $26.31 | +185.06% | 13 | Apr 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $36 | $6.65 | +441.35% | 14 | Apr 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $6 | $2.32 | +158.62% | 5 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $15 | $1.15 | +1,204.35% | 16 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $25 | $3.83 | +552.74% | 2 | Mar 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $50 | $36.36 | +37.51% | 13 | Nov 26, 2024 |
I-Mab
Jul 9, 2025
Reiterates: Buy
Price Target: $7
Current: $2.62
Upside: +167.18%
ImmunityBio
Jun 4, 2025
Reiterates: Buy
Price Target: $8
Current: $2.37
Upside: +237.55%
Aura Biosciences
May 28, 2025
Assumes: Buy
Price Target: $22
Current: $6.75
Upside: +225.93%
Zentalis Pharmaceuticals
May 15, 2025
Reiterates: Buy
Price Target: $10
Current: $1.34
Upside: +646.27%
Corbus Pharmaceuticals Holdings
May 7, 2025
Maintains: Buy
Price Target: $50 → $40
Current: $9.31
Upside: +329.65%
TScan Therapeutics
May 7, 2025
Maintains: Buy
Price Target: $15 → $10
Current: $1.62
Upside: +517.28%
Erasca
Apr 30, 2025
Reiterates: Buy
Price Target: $6
Current: $1.39
Upside: +331.65%
Foghorn Therapeutics
Apr 30, 2025
Reiterates: Buy
Price Target: $13
Current: $5.00
Upside: +160.00%
Sutro Biopharma
Apr 29, 2025
Reiterates: Neutral
Price Target: $2
Current: $0.81
Upside: +146.91%
Protara Therapeutics
Apr 28, 2025
Reiterates: Buy
Price Target: $23
Current: $3.06
Upside: +651.63%
Apr 28, 2025
Reiterates: Buy
Price Target: $75
Current: $26.31
Upside: +185.06%
Apr 3, 2025
Reiterates: Buy
Price Target: $36
Current: $6.65
Upside: +441.35%
Mar 26, 2025
Maintains: Buy
Price Target: $18 → $6
Current: $2.32
Upside: +158.62%
Mar 12, 2025
Reiterates: Buy
Price Target: $15
Current: $1.15
Upside: +1,204.35%
Mar 11, 2025
Reiterates: Buy
Price Target: $25
Current: $3.83
Upside: +552.74%
Nov 26, 2024
Maintains: Buy
Price Target: $40 → $50
Current: $36.36
Upside: +37.51%